Compare USA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USA | HRMY |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2020 |
| Metric | USA | HRMY |
|---|---|---|
| Price | $6.20 | $37.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $51.33 |
| AVG Volume (30 Days) | ★ 880.5K | 779.7K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | N/A | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | N/A | $16.15 |
| P/E Ratio | ★ N/A | $11.94 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $5.62 | $25.52 |
| 52 Week High | $7.09 | $40.93 |
| Indicator | USA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 56.93 |
| Support Level | $6.11 | $37.12 |
| Resistance Level | $6.20 | $40.87 |
| Average True Range (ATR) | 0.06 | 1.36 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 90.00 | 40.59 |
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.